Clinical Scorecard: Unlocking the Multi-Omics Potential of a Blood Spot
At a Glance
| Category | Detail |
|---|---|
| Condition | Dried blood spot (DBS) metabolite and lipid analysis |
| Key Mechanisms | A biphasic Folch-modeled extraction separates lipids into an organic phase and metabolites into an aqueous phase for LC-HRMS/MS analysis from one DBS. |
| Target Population | Research use with DBS specimens; potential diagnostic applications require further method development and clinical validation in samples from affected patients. |
| Care Setting | Laboratory analysis of DBS, including research related to newborn screening; broader diagnostic use has not yet been clinically validated. |
Key Highlights
- The protocol analyzes metabolites and lipids from a single 10 µL DBS specimen.
- Lower reconstitution volume was used to concentrate analytes and improve signal intensity.
- Volumetric DBS devices were used to collect a fixed blood volume and reduce variability related to spot volume and hematocrit.
- DBS results may not be directly comparable with plasma or serum reference values.
- The authors state that further method development and clinical validation are needed before diagnostic application.
Guideline-Based Recommendations
Diagnosis
- The described method is an analytical approach; the article does not provide diagnostic criteria or validated clinical cutoffs.
Management
- The article does not provide treatment or disease-management recommendations.
Monitoring & Follow-up
- Reliability and reproducibility were assessed by performing repeated DBS extractions from the same donors on different days and comparing results.
Risks
- Metabolite and lipid concentrations can differ between DBS whole blood and plasma or serum, limiting direct comparison with reference values from other matrices.
- Drying and storage may alter molecular profiles through oxidation, reduction, or other chemical changes.
- Hematocrit and spot volume can contribute to variability; conventional non-volumetric cards may be affected by blood spreading and punch volume.
Patient & Prescribing Data
No patient treatment population or prescribing data are reported. The method was developed for DBS analysis, with potential future diagnostic use requiring validation in samples from affected patients.
No treatments or prescribing recommendations are discussed. The authors describe potential detection of multiple metabolic and lipid-related disorders from one low-volume specimen, pending further development and clinical validation.
Clinical Best Practices
- Account for specimen matrix when interpreting results; DBS measurements may not be directly comparable with plasma or serum reference values.
- Consider drying, storage, hematocrit, and spot volume as pre-analytical sources of variation.
- Use volumetric DBS devices when a fixed blood volume is required; the described workflow used devices collecting 10 µL.
- The described procedure used glass pipettes and tubes to minimize polyethylene glycol contamination.
- Interpret molecular identifications in the context of the stated analytical workflow: metabolites were processed in MZmine and lipids annotated using LipidMatch.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
